Individual compound research
PDL-RT3 on its own. Review GIP, GLP-1 and glucagon receptor research and its evidence limits.
Individual compound · no catalog companion established
No supporting controlled human combination study with the other catalog peptides was identified in this review. Retatrutide remains investigational; the cited findings do not establish human use of this catalog vial.
Retatrutide is a single investigational molecule with activity at GIP, GLP-1 and glucagon receptors. Its phase 2 obesity trial studied retatrutide against placebo. TRIUMPH-5 compares retatrutide with tirzepatide in separate treatment arms; it does not study taking both together.
Research reviewed September 5, 2026. Sources concern the stated study materials, not this catalog vial; trial registration alone does not establish a combination’s safety or efficacy.
Explore all Reta research stacks
One compound, with its own product record and lot documentation.
1 vial
$120
PDL-RT3 is the catalog alias for a synthetic peptide analogue in the triple incretin-receptor research class. Its laboratory record identifies the underlying analyte separately, while the catalog material is supplied as a sealed vial of lyophilized powder for analytical research.
Lot documentation published
One vial of this product.
Ask about Retatrutide (Reta)
Contact us for current availability and lot documentation for this product.
Laboratory research only. Goal labels describe research themes, not promised outcomes or combined-use guidance. Each product is a separate catalog record. Not for human or veterinary use.